Rafael Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Rafael Holdings, Inc. (RFL) on December 7, 2020. The company is incorporated in Delaware and trades on the New York Stock Exchange. The report details a private placement of equity securities.
Key Financial Metrics and Transaction Details
- Capital Raised: $13 million aggregate purchase price.
- Shares Issued: 567,437 shares of Class B common stock.
- Price Per Share: $22.91 (based on the closing price on December 4, 2020).
- Warrants Issued: 113,487 warrants (20% of shares purchased) with an exercise price of $22.91, expiring June 6, 2022.
- Investors: Two entities, each purchasing 218,245 shares for $5 million. The CEO and Chairman, Howard Jonas, serves on the boards of both purchasing entities.
Material Changes and Use of Proceeds
The filing does not report changes to historical revenue, profit, or cash flow metrics. The material event is the unregistered sale of equity. Proceeds are allocated as follows:
- Primary Use: To exercise a portion of a warrant held by a subsidiary to purchase equity in Rafael Pharmaceuticals, Inc., thereby maintaining the Registrant's relative ownership percentage.
- Secondary Use: Funding drug development programs (including the Barer Institute subsidiary) and general corporate purposes.
Outlook, Risks, and Contingencies
The transaction was conducted under the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933. The filing does not provide specific forward-looking guidance, risk factors, or contingency details beyond the stated intent to maintain equity position and fund operations.
Key Facts for Investor Verification
- Verify the impact of the warrant exercise on the fully diluted equity position in Rafael Pharmaceuticals, Inc.
- Confirm the related-party nature of the transaction involving entities where the CEO serves on the board.
- Monitor the expiration date of the new warrants (June 6, 2022) and potential dilution if exercised.
- Review subsequent filings for updates on the funding of drug development programs.